Q32 Bio: Bempikibart shows 35.3% mean SALT score reduction in alopecia areata Phase 2a

Q32 Bio disclosed additional Week 36 results from Part B of its Phase 2a SIGNAL-AA trial of bempikibart in severe alopecia areata. The study showed clinically meaningful hair regrowth, with responses seen across patient subgroups, supporting a move toward registrational development. Safety was generally well tolerated with no new safety signals.